Barclays Private Equity acquires Fine Chemical specialist CU UETIKON

• Barclays Private Equity acquires 100 percent of CU UETIKON together with management
• Continuation of consistent and successful niche strategy
• Focus on the manufacture of high standard Active Pharmaceutical Ingredients and Fine Chemicals

Read the full press release:

Barclays Private Equity acquires Fine Chemical specialist CU UETIKON